[1] GOU Y,GUO H,ZHANG L,et al. Genomic analysis of anti-hepatitis B virus（HBV） activity by small instable HBV-producing cell[J]. Virology,2005,79（220）：14392-14403.
[2] BENHAMOU Y. Treatment algorithm for chronic hepatitis B in HIV-infected patients[J]. J Hepatol,2006,44（Suppl 1）：s90-s94.
[3] HADZIYANNIS SJ,TASSOPOULOS NS,HEATHCOTE EJ,et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen negative chronic hepatitis B[J]. N Engl J Med,2003,348：800-807.
[4] MARCELLIN P,CHANG TT,LIM SG,et al. Adefovir dipivoxil for he treatment of hepatitis B e antigen-positive chronic hepatitis B[J]. N Engl J Med,2003,348：808-816.
[5] HADZIYANNIS S,TASSOPOULOS N,CHANG TT,et al. Three-year study of adefovir dipivoxil（ADV） demonstrates sustained efficacy in presumed precore mutant chronic hepatitis B patients in a long-term safety and efficacy study[J]. J Hepatol,2004,42（Suppl 1）：17（Abstract 46）.
[6] 中华医学会肝病学分会和感染病学分会. 慢性乙型肝炎防治指南[J]. 实用肝脏病杂志,2006,9（1）：8-18.
[7] WOLTERS LM,NIESTERS HG,DE MAN RA,et al. Nucleoside analogues for chronic hepatitis B[J]. Eur J Gastroenterol Hepatol,2001,13（12）:1499-1506.
[8] 蒋晔,徐智儒,张晓青. 抗乙肝新药阿德福韦酯的研究进展[J]. 中国新药与临床杂志,2004,23（6）：373-377.
[9] ZOULIM F. Assessment of treatment efficacy in HBV infection and disease[J]. J Hepatol,2006,44（Suppl 1）：s95-99.
[10] 张宜俊,郑曲波,刘惠萍,等. 慢性HBV感染者外周血树突状细胞亚群的检测和分析[J]. 上海免疫学杂志,2001,20（6）：16-18. |
